Breaking News SKVI: Skinvisible’s Invisicare Patent Portfolio Strengthens – Hong Kong Patent Granted for Polymer Technology

Skinvisible, Inc. (OTCBB: SKVI)

LAS VEGAS, Jul 27, 2010 (GlobeNewswire via COMTEX) — Skinvisible, Inc. (OTCBB:SKVI) announced today the Hong Kong Patent Office has issued the Company a patent (No. HK1066971) covering its unique polymer delivery system, Invisicare(R). This comprehensive patent is the fourth granted in Asia and the seventh worldwide. The Invisicare patent adds protection in Hong Kong in the areas of “Topical Composition,” “Topical Composition Precursor,” and “Methods for Manufacturing and Using.”

“Patent protection represents a key investment for Skinvisible as it provides our products with long-term market exclusivity,” said Mr. Terry Howlett, President and CEO of Skinvisible. “Patents strengthen our ability to license our unique product formulations worldwide, as evidenced by our recent agreements in Europe, China and the United States. We are aggressively pursuing additional licensing opportunities for formulations developed with the Invisicare technology.”

The patented Invisicare technology can be applied to a variety of topical products for medical conditions and uses, especially where a controlled release of the active ingredient and substantivity are the desired benefit. Its uniqueness stems from an ability to deliver a wide range of active ingredients, holding them on the skin while providing a controlled release. The cream and gel formulations made with Invisicare have a smooth feel which form an undetectable film that delivers the active ingredient while supporting the skin’s natural barrier function. This technology provides life cycle management for topical products that require new patent protection, revitalization and a new story.

Skinvisible holds patent protection for Invisicare in the United States, Australia, India, China, South Korea, Japan and now Hong Kong. The Company has numerous US and international product patents pending covering both the technology and finished product formulations.

About Skinvisible Pharmaceuticals, Inc.

Skinvisible is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing irritation. Skinvisible receives a combination of research and development fees, license fees, and royalties for the life of the patent. Skinvisible’s value also lies in its ability to continually generate new IP on topical products formulated with Invisicare. &

The Skinvisible, Inc. logo is available at

Forward-Looking Statements: This press release contains ‘forward looking’ statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending March 30, 2010).


StockGuru is STOCKGURU.COM. 1601 Berwick Drive, McKinney, Texas 75070 – (469) 252-3030. Disclosure: StockGuru entered into an investor relations consulting and market awareness contract on July 12, 2010. The company has agreed to pay us five thousand dollars per month in cash for the period of six months, totaling thirty thousand USD. StockGuru was previously compensated 500,000 144 restricted common shares by the company for profile coverage for the period ending January 30, 2010. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. To further clarify, we will not be buying or selling shares for the period of July 12, 2010 through January 12, 2011. We hold no shares and will not be receiving further compensation that is share related during this period. StockGuru is not a registered investment adviser or a broker/dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.